Alexion - Innovative Drugs For Orphan Diseases Focus = Stability!
Abstract
Alexion (ALXN) products lack any near term competition and patent cliff vs. other biologics. 3Q12 earnings repeatedly showed the growth of Soliris (L, PNH, aHUS) in various geographies. Further growth would be boosted from label expansion in other indications targeting rare and high unmet need and the products beyond Soliris. The fall in the stock price of Alexion (ALXN) despite robust 3Q12 earnings presents a long term buying opportunity … For more detail, please read our report released on 31st September, 2012, titled, “ Innovative Drugs for Orphan Diseases Focus = Stability!”
Alexion (ALXN) products lack any near term competition and patent cliff vs. other biologics. 3Q12 earnings repeatedly showed the growth of Soliris (L, PNH, aHUS) in various geographies. Further growth would be boosted from label expansion in other indications targeting rare and high unmet need and the products beyond Soliris. The fall in the stock price of Alexion (ALXN) despite robust 3Q12 earnings presents a long term buying opportunity … For more detail, please read our report released on 31st September, 2012, titled, “ Innovative Drugs for Orphan Diseases Focus = Stability!”
